Skip to content
Catalyst

PapersPMID:38068797

The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis-A Double-Blind Placebo-Controlled Trial.

Nutrients2023The record ↗

  1. Finding, moderate evidenceno difference foundTotal nasal symptom score (TNSS)

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “No significant difference was seen between the Levagen+ and placebo groups for the allergy symptoms scores (rTNSS) at baseline or throughout the 14 days of treatment.”
    Study
    RCT
    Duration
    14 days
    Dose studied
    Levagen+ (PEA) 350 mg daily, two 175 mg capsules each morning, against placebo of 175 mg maltodextrin per capsule
    Population
    Adults aged 21 to 77 years with seasonal allergic rhinitis, 108 randomised and 101 completed; whole-population comparison, reflective total nasal symptom score recorded online twice daily

Study record

Design
randomised controlled trial
Species
human
Population
otherwise healthy adults aged 18 years or older with seasonal allergic rhinitis
Participants
108
Comparator
placebo
Duration
14 days
Endpoints measured
14